Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG301 SC Injection in Primary Immune Thrombocytopenia
NCT07710248Phase 2Recruiting
- Sponsor
- Shangjian Bio
- Start
- Jun 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 2 trial of SG301 in primary immune thrombocytopenia (ITP), sponsored by Shangjian Bio. Started Jun 2026; status: recruiting.
02
Drugs
SG301
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07710248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710248.